Initial Phase 1 clinical data for Schrödinger's investigational MALT1 inhibitor SGR-1505 will be presented at two major hematology conferences in June 2025, showcasing its potential in treating relapsed/refractory B-cell malignancies.
Schrödinger achieved total revenue of $59.6 million in Q1 2025, representing a 63% increase compared to the same period last year, with software revenue growing 46% to $48.8 million.